



**Link** Pharma Chem Ltd.  
ISO-9001 - 2015  
ISO-14001 - 2015

**REGISTERED OFFICE :**

Plot No. 161, 161/1, 162, G.I.D.C.,  
Nandesari - 391340,  
Dist. Baroda (Gujarat) (India)  
Tel. (O) (0265) 2840281 / 2840282  
E-Mail : linkpharmalimited@gmail.com  
CIN: L24230GJ1984PLC007540

Date: 10.11.2020

To,  
Department of Corporate Services,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

**Ref: Submission of Unaudited Financial Results for the Quarter and Half Year ended on September 30, 2020 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that the Board of Directors at its meeting held today considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2020.

The Unaudited Financial Results of the Company and the Limited Review Report of the Statutory Auditors on the aforesaid results are enclosed.

The Meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 1:30 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
For Link Pharma Chem Limited

Bhushan Joshi  
Company Secretary



Encl: As above.



**Link Pharma Chem Ltd.**  
ISO-9001 - 2015  
ISO-14001 - 2015

**REGISTERED OFFICE :**

Plot No. 161, 161/1, 162, G.I.D.C.,  
Nandesari - 391340,  
Dist. Baroda (Gujarat) (India)  
Tel. (O) (0265) 2840281 / 2840282  
E-Mail : linkpharmalimited@gmail.com  
CIN : 294930AJ1984PLC007540

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2020**

(in Rs. Lakhs)

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Income :</b>						
Revenue from operations	856.01	510.02	672.24	1,366.03	1,229.83	2,547.10
Other income	0.41	0.02	0.43	0.43	0.43	10.19
<b>Total Income (A)</b>	<b>856.42</b>	<b>510.04</b>	<b>672.67</b>	<b>1,366.46</b>	<b>1,230.25</b>	<b>2,557.29</b>
<b>Expenses:</b>						
Cost of materials consumed	388.31	127.57	234.23	515.88	388.55	890.41
Changes in inventories of finished goods and work-in-progress	37.82	(9.89)	51.00	27.93	117.68	100.93
Employee benefits expense	144.44	113.18	136.32	257.62	256.05	498.55
Finance costs	11.17	10.34	6.25	21.51	16.03	36.12
Depreciation and amortization expense	23.19	23.20	22.37	46.39	44.74	92.79
Other Expenses	215.20	201.16	220.15	416.36	369.19	794.37
<b>Total expenses (B)</b>	<b>820.13</b>	<b>465.55</b>	<b>670.32</b>	<b>1,285.69</b>	<b>1,192.24</b>	<b>2,413.17</b>
<b>Profit before tax (C) = (A-B)</b>	<b>36.29</b>	<b>44.49</b>	<b>2.35</b>	<b>80.77</b>	<b>38.01</b>	<b>144.12</b>
<b>Tax expense:</b>						
(1) Current tax	0.92	12.00	-2.95	12.92	7.31	27.59
(2) MAT credit recognised	10.00	-	-	10.00	-	30.44
(3) Deferred tax	(1.37)	-	-	(1.37)	-	(8.89)
<b>Total tax expense (D)</b>	<b>9.55</b>	<b>12.00</b>	<b>-2.95</b>	<b>21.55</b>	<b>7.31</b>	<b>49.14</b>
<b>Profit for the year (E) = (C-D)</b>	<b>26.74</b>	<b>32.49</b>	<b>5.29</b>	<b>59.22</b>	<b>30.70</b>	<b>94.98</b>
<b>Other Comprehensive Income (F)</b>						
Items that will not be reclassified to profit or loss	3.00	-	-0.49	3.00	(3.00)	8.03
Income tax effect on above	(0.60)	-	0.25	(0.60)	0.75	2.14
	2.40	-	-0.24	2.40	(2.25)	10.17
<b>Total comprehensive income for the year (G) = (E+F)</b>	<b>29.14</b>	<b>32.49</b>	<b>5.05</b>	<b>61.62</b>	<b>28.45</b>	<b>105.15</b>
Paid up Equity Share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06	444.06
Earnings per equity share (Face value of Rs. 10) (Rs.)						
Basic and Diluted	0.60	0.73	0.11	1.33	0.69	2.14

**NOTES:**

- These Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10th November, 2020
- The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment Reporting.
- This statement is as per regulation 33 of the SEBI (listing Obligations and Disclosure Requirement) Regulations, 2015.
- The full impact of COVID-19 still remains uncertain and could be different from our estimates when we prepared these financial results. The Company will continue to closely monitor any material changes to future economic conditions.
- The Company confirms that its Statutory Auditors, M/s Sanjay Soni & Associates, have issued unmodified opinion on the financial results.

For and behalf of the Board of  
Link Pharma Chem Limited



*[Signature]*

Satish G. Thakur  
Chairman & Whole-time Director  
(DIN: 00292129)

Date: 10/11/2020

Place: Vadodara



# Link Pharma Chem Ltd.

ISO-9001 - 2015  
ISO-14001 - 2015

## REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C.,  
Nandesari - 391340,  
Dist. Baroda (Gujarat) (India)  
Tel. (O) (0265) 2840281 / 2840282  
E-Mail : linkpharmalimited@gmail.com  
CTIN: L24230GJ1984PLC007540

### STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2020

Particulars	As at 30th September, 2020 (Unaudited)	As at 31st March, 2020 (Audited)
<b>I. ASSETS</b>		
<b>1. NON CURRENT ASSETS</b>		
(a) Property, Plant and Equipment	888.61	880.54
(b) Financial Assets		
i) Investments	2.92	2.92
ii) Other financial assets	64.90	32.99
(c) Income tax assets (Net)	8.44	5.84
(d) Other non-current assets	48.51	66.10
<b>Total non-current assets</b>	<b>1,013.37</b>	<b>988.39</b>
<b>2. CURRENT ASSETS</b>		
(a) Inventories	230.02	163.13
(b) Financial Assets		
(i) Trade receivables	532.36	499.41
(ii) Cash and cash equivalents	542.17	187.04
(iii) Bank Balances other than (ii) above	15.98	18.21
(iv) Loans	3.91	4.63
(v) Other financial assets	2.54	1.25
(c) Other current assets	68.07	34.67
<b>Total current assets</b>	<b>1,395.05</b>	<b>908.33</b>
<b>Total Assets</b>	<b>2,408.42</b>	<b>1,896.72</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	444.06	444.06
(b) Other equity	760.87	699.25
<b>Total Equity</b>	<b>1,204.93</b>	<b>1,143.31</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Borrowings	395.40	316.75
(b) Provisions	-	-
(c) Deferred tax liabilities (Net)	89.89	91.26
<b>Total non-current liabilities</b>	<b>485.30</b>	<b>408.01</b>
<b>Current liabilities</b>		
<b>(a) Financial liabilities</b>		
(i) Borrowings	-	-
(ii) Trade payables	655.76	301.11
(ii) Other financial liabilities	29.89	39.18
<b>(b) Other current liabilities</b>	32.55	5.11
<b>Total current liabilities</b>	<b>718.19</b>	<b>345.40</b>
<b>Total Equity and liabilities</b>	<b>2,408.42</b>	<b>1,896.72</b>

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements.

For Link Pharma Chem Limited

Satish G. Thakur  
Chairman & Whole-time Director  
(DIN: 00292129)

Date: 10/11/2020  
Place: Vadodara





**Link** Pharma Chem Ltd.  
ISO-9001 - 2015  
ISO-14001 - 2015

**REGISTERED OFFICE :**

Plot No. 161, 161/1, 162, G.I.D.C.,  
Nandesari - 391340,  
Dist. Baroda (Gujarat) (India)  
Tel. (O) (0265) 2840281 / 2840282  
E-Mail : linkpharmalimited@gmail.com  
CTN: L949306J1984PLC007540


**STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020**

Particulars	As on 30th September, 2020 (Unaudited)	As on 30th September, 2019 (Unaudited)
<b>A CASHFLOW FROM OPERATING ACTIVITIES</b>		
PROFIT BEFORE TAX	80.77	38.01
Adjustment for :		
Depreciation and Amortisation Expenses	46.39	44.74
Financial Cost	21.51	16.03
Profit/Loss on Sale of Fixed Assets	0.61	25.90
Income From Investment ( Int earned)	-	-0.40
Operating Profit before Working Capital Changes	149.28	124.29
Changes in Working Capital :		
Inventories	-66.89	124.74
Trade Receivables and Loans & Advances	-97.53	-156.51
Trade Payables, Other CurrentLiabilities and Provisions	385.08	58.19
Cash Generated from Operations	369.94	150.71
Direct Taxes paid	-26.12	10.60
<b>Net Cash from Operating Activities</b>	<b>343.82</b>	<b>161.31</b>
<b>B Cash Flow from Investing Activities</b>		
Purchase of Fixed Assets	-36.87	-81.96
Sale of Fixed Assets	-0.61	-
income from investment	0.94	0.40
<b>Net CashFlow From Investing Activities</b>	<b>-36.54</b>	<b>-81.56</b>
<b>C Cash Flow from Financing Activities</b>		
Government Subsidy Received		
Proceeds of borrowing	69.36	-61.16
Finance Cost	-21.51	-16.03
Dividend Paid		
Tax on dividend paid		
<b>Net Cash Used in Financial Activities</b>	<b>47.85</b>	<b>-77.19</b>
<b>Net Increase in Cash &amp; Cash Equivalents</b>	<b>355.13</b>	<b>2.56</b>
<b>Cash and Cash Equivalents as at the Beginning of Year</b>	<b>187.04</b>	<b>2.47</b>
<b>Cash and Cash Equivalents as at the End of the Year</b>	<b>542.17</b>	<b>5.03</b>

Date: 10/11/2020  
Place: Vadodara



For Link Pharma Chem Limited

  
Satish G. Thakur  
Chairman & Whole-time Director  
(DIN: 00292129)

**S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.**  
(O) : 0265-2983872, (M) : 98254 83162, E-mail : sanjaysoni@gmail.com


**Independent Auditors' Review Report on Unaudited Quarterly and year to date Financial Results date Result of Link Pharma Chem Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

**TO THE BOARD OF DIRECTORS OF  
LINK PHARMA CHEM LIMITED**

- 1 We have reviewed the accompanying statement of Unaudited financial Results of LINK PHARMA CHEM LTD. ("the Company"), for the Quarter and half year ended September 30, 2020 ("the statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulation"). This statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- 2 We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3 Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other recognised accounting practice and policies has not disclosed the information required to be disclosed in terms of regulation, read with the circular, including the manner in which it is to be disclosed, or the it contains any material misstatement.

**For SANJAY SONI & ASSOCIATES  
Chartered Accountants  
FRN 113251W**





**CA Sanjay Soni  
Partner**

**M. No. 040616**

**UDIN 20040616AAAABA1554**

**Place: Baroda  
Date: 10.11.2020**